Pharmacologic prevention of post-ERCP pancreatitis: is nitroglycerin a sangreal?
Muralidharan
Visvanathan
V
Jamidar
Priya
P
D002404:Catheterization / Q000009:adverse effects; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D006801:Humans; D005996:Nitroglycerin / Q000627:therapeutic use*; D010195:Pancreatitis / Q000517:prevention & control*; D013035:Spasm / Q000209:etiology*; D046628:Sphincter of Oddi Dysfunction / Q000209:etiology*; D015607:Stents; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D005996:Nitroglycerin